Androsterone-based therapy for blood sugar disease (autoimmune diabetes (TIDM)):  Dehydroepiandrosterone (DHEA) and its metabolite HE3286 (17α-ethynyl-5-androstene-3β,7β,17β-triol)  increase PD-L1 expression,  augment Tregs function, promote immune tolerance, increase pancreatic β-cell proliferation and regeneration, increase insulin secretion, improve insulin sensitivity, increase energy utilization, and reverse TIDM, via up regulation of its target gene, 18/April/2018,  10.40 pm